• user-img

    Vikshita Vitthal Gujaran in News

    15-Mar-2023 10:38 AM


    Sun Pharma Bags A Potential Derma Segment Winner With Latest Buy, Says Jefferies

    Sun Pharmaceutical Industries Ltd.'s acquisition of Concert Pharmaceuticals Inc. added a complementary derma product to its existing line of specialty products, according to Jefferies.
    The brokerage expects a pre-tax net present value of Rs 64 per share from the acquisition of the U.S.-based late-stage clinical biopharmaceutical company on March 6.
    The brokerage continues to maintain a "buy" rating on the stock and a target price of Rs 1,200 apiece, implying an upside of 26%.
    The return potential of the stock implies an upside of 20.8%.

    Source -